Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, sales of Sodium Hyaluronate, focusing on Cosmetics, Medical, Pharmaceutical Grade HA

    Virtual Booth

    Contact Supplier

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    China

    Virtual Booth

    Contact Supplier

    Menu

    Imeglimin hydrochloride (JAN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 86Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Twymeeg Data Presented at 68th Japan Diabetes Society Meeting
    Twymeeg Data Presented at 68th Japan Diabetes Society Meeting

    28 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250527120457/en/New-Clinical-and-Scientific-Data-on-TWYMEEG-to-be-Presented-at-the-68th-Annual-Meeting-of-the-Japan-Diabetes-Society

    BUSINESSWIRE
    28 May 2025
    Share Share
    Poxel Patent Granted In China For Imeglimin In Renal Impairment
    Poxel Patent Granted In China For Imeglimin In Renal Impairment

    20 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250120680560/en

    BUSINESSWIRE
    20 Jan 2025
    Share Share
    Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update
    Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240908901962/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share
    Poxel Updates Q2 Financials Reschedules Annual General Meeting
    Poxel Updates Q2 Financials Reschedules Annual General Meeting

    15 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240714885795/en

    BUSINESSWIRE
    15 Jul 2024
    Share Share
    Poxel to Report Its 2023 Annual Results by the End of April 2024
    Poxel to Report Its 2023 Annual Results by the End of April 2024

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328548115/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA
    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA

    03 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221002005044/en

    BUSINESSWIRE
    03 Oct 2022
    Share Share